MXPA04005366A - PRODUCTION OF CHIRALLY PURE alpha-AMINO ACIDS ADN N-SULFONYL alpha-AMINO ACIDS. - Google Patents

PRODUCTION OF CHIRALLY PURE alpha-AMINO ACIDS ADN N-SULFONYL alpha-AMINO ACIDS.

Info

Publication number
MXPA04005366A
MXPA04005366A MXPA04005366A MXPA04005366A MXPA04005366A MX PA04005366 A MXPA04005366 A MX PA04005366A MX PA04005366 A MXPA04005366 A MX PA04005366A MX PA04005366 A MXPA04005366 A MX PA04005366A MX PA04005366 A MXPA04005366 A MX PA04005366A
Authority
MX
Mexico
Prior art keywords
alpha
amino acids
chirally pure
salt
sulfonyl
Prior art date
Application number
MXPA04005366A
Other languages
Spanish (es)
Inventor
Resnick Lynn
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46204648&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MXPA04005366(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US10/014,304 external-priority patent/US6610734B2/en
Priority claimed from US10/166,896 external-priority patent/US6657070B2/en
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of MXPA04005366A publication Critical patent/MXPA04005366A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/64—Sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/30—Hetero atoms other than halogen
    • C07D333/34—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Psychiatry (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Methods for production of chirally pure alpha-amino acids and N-sulfonyl alpha-amino acids are described. An aldehyde and a cyanide salt are reacted with an alpha-methylbenzylamine to afford a product. The product reacts with a strong acid, is neutralized, and is extracted. The resulting product is subsequently hydrogenated and hydrolyzed to provide a product which is dissolved in a strong acid to provide a salt of a chirally pure alpha-amino acid, which is reacted to provide the chirally pure alpha-amino acid. Another method involves mixing ephedrine hemihydrate and an N-sulfonyl alpha-ethylnorvaline in ethanol at a molar ratio of 1:1; heating the mixture to dissolve the solids; cooling to allow formation of a precipitate; washing with an organic solvent to give diastereomeric salt; recrystallizing the salt; dissolving the recrystallized salt in an organic solvent and strong aqueous acid, separating the layers; washing the organic extract; drying and concentrating to provide chirally pure N-sulfonyl alpha-amino acid.
MXPA04005366A 2001-12-11 2002-11-26 PRODUCTION OF CHIRALLY PURE alpha-AMINO ACIDS ADN N-SULFONYL alpha-AMINO ACIDS. MXPA04005366A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10/014,304 US6610734B2 (en) 2000-12-13 2001-12-11 Heterocyclic sulfonamide inhibitors of beta amyloid production
US10/166,896 US6657070B2 (en) 2000-12-13 2002-06-11 Production of chirally pure α-amino acids and N-sulfonyl α-amino acids
PCT/US2002/038117 WO2003050062A2 (en) 2001-12-11 2002-11-26 PRODUCTION OF CHIRALLY PURE α-AMINO ACIDS ADN N-SULFONYL α-AMINO ACIDS

Publications (1)

Publication Number Publication Date
MXPA04005366A true MXPA04005366A (en) 2004-09-27

Family

ID=46204648

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA04005366A MXPA04005366A (en) 2001-12-11 2002-11-26 PRODUCTION OF CHIRALLY PURE alpha-AMINO ACIDS ADN N-SULFONYL alpha-AMINO ACIDS.

Country Status (7)

Country Link
EP (1) EP1461332A4 (en)
JP (1) JP4615861B2 (en)
AU (2) AU2002351170B8 (en)
CA (1) CA2470111A1 (en)
MX (1) MXPA04005366A (en)
TW (1) TWI260316B (en)
WO (1) WO2003050062A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE330950T1 (en) 2000-12-13 2006-07-15 Wyeth Corp HETEROCYCLIC SULFONAMIDES AS INHIBITORS OF BETA-AMYLOID PRODUCTION
US7300951B2 (en) 2003-03-31 2007-11-27 Wyeth Fluoro- and trifluoroalkyl-containing heterocyclic sulfonamide inhibitors of beta amyloid production and derivatives thereof
ES2330451T3 (en) 2004-01-16 2009-12-10 Wyeth HETEROCICLIC SULFONAMID BASED INHIBITORS FROM THE PRODUCTION OF BETA-AMYLOOIDS CONTAINING AN AZOL.
MX2008013539A (en) 2006-04-21 2008-10-29 Wyeth Corp Production of chirally pure amino alcohol intermediates, derivatives thereof, and uses thereof.

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3802981A1 (en) * 1988-02-02 1989-08-10 Basf Ag METHOD FOR REDUCING REDUCABLE CONNECTIONS
US5264577A (en) * 1992-04-22 1993-11-23 Warner-Lambert Company Cyclic amino acids and derivatives thereof
DK0656887T3 (en) * 1992-08-25 1999-07-05 Searle & Co Hydroxyethylaminosulfonamides for use as inhibitors of retroviral proteases
US5968942A (en) * 1992-08-25 1999-10-19 G. D. Searle & Co. α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors
US6191306B1 (en) * 1999-08-03 2001-02-20 Eastman Chemical Company Process for the preparation of cyclopropylglycine

Also Published As

Publication number Publication date
WO2003050062A3 (en) 2003-11-20
AU2009251195A1 (en) 2010-01-21
EP1461332A4 (en) 2009-10-21
EP1461332A2 (en) 2004-09-29
JP4615861B2 (en) 2011-01-19
CA2470111A1 (en) 2003-06-19
AU2002351170B2 (en) 2009-09-24
AU2002351170B8 (en) 2009-10-08
AU2002351170A1 (en) 2003-06-23
JP2005511727A (en) 2005-04-28
WO2003050062A2 (en) 2003-06-19
TWI260316B (en) 2006-08-21
TW200306292A (en) 2003-11-16

Similar Documents

Publication Publication Date Title
US8680329B2 (en) Process for preparation of α-ketoglutaric acid
CN110252395B (en) Catalyst for preparing high-purity taurine and application thereof
CN101830818B (en) Method for preparing anhydrous betaine
JP2010507701A5 (en)
GB2437006A (en) Salts assisted selective extraction of 6-acetyl-4.1',6'trichlorogalactosucrose and 4,1',6'trichlorogalactosucrose from aqueous reaction mixture
MXPA04005366A (en) PRODUCTION OF CHIRALLY PURE alpha-AMINO ACIDS ADN N-SULFONYL alpha-AMINO ACIDS.
NO20080812L (en) Process for Preparation of 4 β-Amino-4'-demethyl-4-4-deoxy podophyllotoxin
CN101560132B (en) Method for racemizing chiral amino acid or derivatives of chiral amino acid
CN108558688A (en) A method of preparing Beta-alanine using β-aminopropionitrile
CN106518840A (en) Synthetic method of 5-chloro-2-thiophenecarboxylic acid
CN106008392B (en) A kind of preparation method of the intermediate of cancer therapy drug Dasatinib
CN106905262A (en) A kind of method for preparing the HEPES of high-purity 4
CN105481624B (en) The catalysis oxidation synthetic method of Arneel SD
CN104326989A (en) Preparation method of 2-methyl-4-amino-5-(aminomethyl) pyrimidine
CN113501771B (en) Preparation method of N- (2-aminoethyl) glycine derivative
CN110606811B (en) Synthetic method of L-serine methyl ester hydrochloride
WO2019218445A1 (en) Method for synthesizing urease inhibitor acetohydroxamic acid
CN103319376B (en) The preparation method of creatine hydrochloride
JP2009062392A (en) Cyclization process
AU2002233613A1 (en) Process and apparatus for the production of calcium bromide by liquid-liquid extraction
CN109280049B (en) Synthetic method of medical compound avanafil
CN102718663A (en) Synthesis method of 5-chloro-1-indene amine
CN103242236B (en) Preparation method for synthesizing substituted benzimidazole by taking acrylonitrile as nitrogen source
RU2124497C1 (en) Method of preparing 1-adamantanecarboxylic acid
CN105440023A (en) Synthetic method of EPZ-6438

Legal Events

Date Code Title Description
FG Grant or registration